http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#Head http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#assertion http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#provenance http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#pubinfo http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#assertion http://purl.obolibrary.org/obo/DOID_4450 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_4450 http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09078 http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association http://www.w3.org/2000/01/rdf-schema#label lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc 1 1 in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy 1 2 for the first line treatment of patients with unresectable hepatocellular carcinoma hcc 1 3 lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy lenvima is indicated for the first line treatment of patients with unresectable hepatocellular carcinoma hcc http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09078 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#provenance http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#pubinfo http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#sig http://purl.org/nanopub/x/hasSignature dZisx9uGdzZltCSmanjlLwXJLyBZaMWkUM0aQkqzBAki/VxTGpTxUsdde6cY8VHCCko6pEs466/ZO0xHsGfbei7i1cie6ckagN5aVVvzzpTp14WoSoNZE+5sA/4F4FtVUp6L37uMSIDa/ikFwJ/AGT3c5X5XxgquG9OgYd6x2Hk= http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://purl.org/dc/terms/created 2021-06-12T12:16:45.381+02:00 http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA9OlXFdM2XuinwH5A1gY03jTUstU4suHJcKEam7qm95c https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs